Arun Kumar, V. A. published the artcileInsights into binding of potential antitumor quinoxaline analogues against Cyclin dependent kinase 2 using docking studies, Recommanded Product: 2,3,6,7-Tetrachloroquinoxaline, the main research area is quinoxaline analog anticancer CDK2 therapeutic target mol docking cancer.
Cyclin-dependent kinases (CDKs) belongs to a family of protein kinases and CDK2 considered as potential anti-cancer target among CDKs. A CDK2 inhibitor is a chem. that inhibits the function of CDKs and prevents over proliferation of cancer cells thus used to treat cancers. Quinoxaline and its derivatives are an important class of benzoheterocycles displaying a broad spectrum of biol. activities which have made them privileged structures in pharmacol. active compounds Modification in their structure has offered a high degree of diversity that has proven useful for the development of new therapeutic agents having improved potency and lesser toxicity. In the present work, attempts were made to identify leading quinoxaline moieties as candidate drugs against CDK2 by carrying out docking experiments with our inhouse synthetic 46 analogs and assigning docking scores. Ten moieties with docking score -5 or above were zoomed in as candidate moieties. Structural features of the above quinoxaline analogs will be presented with a view to arrive at potential drug target for CDK2.
Journal of Chemical, Biological and Physical Sciences published new progress about Antitumor agents. 25983-14-6 belongs to class quinoxaline, name is 2,3,6,7-Tetrachloroquinoxaline, and the molecular formula is C8H2Cl4N2, Recommanded Product: 2,3,6,7-Tetrachloroquinoxaline.
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider